Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $20.00.

ENTA has been the subject of several recent research reports. Evercore ISI raised Enanta Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, August 6th. JMP Securities reissued a "market outperform" rating and issued a $22.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, October 9th. JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating for the company in a report on Tuesday, August 6th. Finally, HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th.

Enanta Pharmaceuticals Trading Up 2.3 %

Shares of ENTA traded up $0.26 during trading hours on Wednesday, hitting $11.52. The company had a trading volume of 143,291 shares, compared to its average volume of 200,351. The company has a market capitalization of $244.10 million, a PE ratio of -2.11 and a beta of 0.56. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $17.80. The company's fifty day moving average price is $11.62 and its two-hundred day moving average price is $12.67.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.36. The firm had revenue of $17.97 million during the quarter, compared to analyst estimates of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The business's revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.27) EPS. Analysts forecast that Enanta Pharmaceuticals will post -5.3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ENTA. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at $35,000. US Bancorp DE boosted its holdings in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 4,243 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in shares of Enanta Pharmaceuticals in the 1st quarter valued at $118,000. Virtu Financial LLC purchased a new stake in shares of Enanta Pharmaceuticals in the 1st quarter valued at $191,000. Finally, Quest Partners LLC boosted its holdings in shares of Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $150,000 after acquiring an additional 9,692 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.